Investors Scrutinize Fulcrum, Weave, and Baldwin Acquisitions

The investigation centers on the merger between Fulcrum Therapeutics and Slate Medicines, which would leave existing Fulcrum shareholders with a 5% stake in the combined entity. Simultaneously, the firm is examining the sale of Weave Communications to Francisco Partners at $7.40 per share and the acquisition of Baldwin Group by Sequence Holdings and DFO Management for $32.50 per share.

Attorneys Daniel Sadeh and Zachary Halper suggest these deals may violate federal securities laws by failing to provide adequate value or transparency. The firm is currently evaluating whether to seek increased financial compensation or additional disclosures for stakeholders. Investors affected by these transactions are being invited to review their legal standing, with the firm operating on a contingent fee basis for those pursuing claims.